A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis

Trial Profile

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Voclosporin (Primary)
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AURORA
  • Sponsors Aurinia Pharmaceuticals
  • Most Recent Events

    • 15 Jan 2018 New source identified and integrated (JapicCTI183821; Japan Pharmaceutical Information Center - Clinical Trials Information).
    • 14 Nov 2017 According to an Aurinia Pharmaceuticals media release, for New Drug Application (NDA) process, the first module will be submitted in the second half of 2018.
    • 20 Oct 2017 According to an Aurinia Pharmaceuticals media release, enrollment is expected to complete in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top